Histone-deacetylase inhibitors and demethylating agents can re-induce FOLH1 expression in low-expression PSMA tumours, potentially making them susceptible to PSMA-targeted radioligands, but this remains validated only in vitro and requires further exploration [14]. This evidence concerns the gene FOLH1 and neoplasm.